**It’s About Time: Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy**

Jason R. Westin and Razelle Kurzrock

**Restoration of miR-200c to Ovarian Cancer Reduces Tumor Burden and Increases Sensitivity to Paclitaxel**

Diana M. Cittelly, Irina Dimitrova, Erin N. Howe, Dawn R. Cochrane, Annie Jean, Nicole S. Spoelstra, Monique A. Spillman, and Jennifer K. Richer

**Dual Systemic Tumor Targeting with Ligand-Directed Phage and Grp78 Promoter Induces Tumor Regression**

Azadeh Kia, Justyna M. Przystal, Nastasia Nianiaris, Nicholas D. Mazarakis, Paul J. Mintz, and Amin Hajitou

**Dll4-Fc, an Inhibitor of Dll4-Notch Signaling, Suppresses Liver Metastasis of Small Cell Lung Cancer Cells through the Downregulation of the NF-κB Activity**


**Targeting Olfactomedin-like 3 Inhibits Tumor Growth by Impairing Angiogenesis and Pericyte Coverage**

Marijana Miljkovic-Licina, Philippe Hammel, Sarah Garrido-Urbani, Boris P.-L. Lee, Mehdi Meguenani, Chiraz Chaabane, Marie-Luce Bochaton-Piallat, and Beat A. Imhof

**RSK2Ser227 at N-Terminal Kinase Domain Is a Potential Therapeutic Target for Multiple Myeloma**

Yuji Shimura, Junya Kuroda, Masaki Ri, Hisao Nagoshi, Mio Yamamoto-Sugitani, Tsutomu Kobayashi, Miki Kyotani, Ryuko Nakayama, Shinsuke Mizutani, Yoshiaki Chinen, Natsumi Sakamoto, Yosuke Matsumoto, Shigoe Horiike, Yukiama Shiotsu, Shinsuke Iida, and Masafumi Taniwaki

**Sorafenib-Mediated Targeting of the AAA+ ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death**


**Contrary Regulation of Bladder Cancer Cell Proliferation and Invasion by Dexamethasone-Mediated Glucocorticoid Receptor Signals**

Yichun Zheng, Koji Izumi, Yi Li, Hitoshi Ishiguro, and Hiroshi Miyamoto

**Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib**

Jaime Acquaviva, Donald L. Smith, Jim Sang, Julie C. Friedland, Suqin He, Manuel Sequeira, Chaohua Zhang, Yumiko Wada, and David A. Proia

**BMS-754807, a Small-Molecule Inhibitor of Insulin-like Growth Factor-1 Receptor/Insulin Receptor, Enhances Gemcitabine Response in Pancreatic Cancer**

Niranjan Awasthi, Changhua Zhang, Winston Ruan, Margaret A. Schwarz, and Roderich E. Schwarz

**Targeting the Inhibitor of Apoptosis Proteins as a Novel Therapeutic Strategy in Medulloblastoma**

Joanna Keating, Maria Tsoli, Andrew R. Hallahan, Wendy J. Ingram, Michelle Haber, and David S. Ziegler
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

Matthias Friedrich, Tobias Raum, Ralf Lutterbuese, Markus Voelkel, Petra Deegen, Doris Rau, Roman Kischel, Patrick Hoffmann, Christian Brandl, Joachim Schuhmacher, Peter Mueller, Ricarda Finnern, Melanie Fuer gut, Dieter ZoPf, Jerry W. Slookstra, Patrick A. Baueuerle, Benno Rattel, and Peter Kufer

Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production


Development of Gene Expression-Based Score to Predict Sensitivity of Multiple Myeloma Cells to DNA Methylation Inhibitors

Jérôme Moreaux, Thierry Rème, Wim Leonard, Jean-Luc Veyrune, Guilhem Requirand, Hartmut Goldschmidt, Dirk Hose, and Bernard Klein

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

Angela Romanelli, Anderson Clark, Franck Assayag, Sophie Chateau-Joubert, Marie-France Poupon, Jean-Luc Servely, Jean-Jacques Fontaine, Xiaohong Liu, Edward Spooner, Samantha Goodstal, Patricia de Cremoux, Ivan Bièche, Didier Decaudin, and Elisabetta Marangoni

SPOTLIGHT ON CLINICAL RESPONSE

Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine

James S. Wilmott, Varsha Tembe, Julie R. Howle, Raghwa Sharma, John F. Thompson, Helen Rizos, Roger S. Lo, Richard F. Kefford, Richard A. Scodyer, and Georgina V. Long

Acknowledgment to Reviewers

ABOUT THE COVER

Olfactomedin-like 3 (Olfm3), a proangiogenic cue and a BMP4 agonist, is produced by both tumor endothelial cells and accompanying pericytes and deposited in the perivascular compartment. Blocking Olfm3 regresses the tumor vasculature, decreases pericyte coverage, and inhibits the progression of tumors. Olfm3 blockade provides an alternative strategy to control tumor growth by targeting a single molecule that affects two distinct cell types within the tumor microenvironment. For details, see article by Miljkovic-Licina and colleagues on page 2588.